Nifty
:
22795.90
Sensex
:
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)
Nifty
Sensex
:
:
22795.90
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)

Kwality Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 539997 | NSE: Not Listed

NSE BSE
818.70
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  817.95
  •  825.95
  •  800.05
  •  813.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4739
  •  38.73
  •  1069.95
  •  405.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 727.42
  • 24.48
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 822.17
  • N/A
  • 2.92

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.83%
  • 2.14%
  • 33.24%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 9.79%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.35
  • 17.13
  • -12.35

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 35.11
  • 36.06
  • -17.32

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 38.60
  • 23.39
  • -41.68

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.14
  • 24.31
  • 24.57

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.80
  • 4.39
  • 3.17

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.18
  • 9.98
  • 7.88

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
84.41
78.09
8.09%
90.03
69.65
29.26%
80.08
67.45
18.72%
91.98
68.80
33.69%
Expenses
66.91
61.41
8.96%
70.37
54.42
29.31%
62.74
53.68
16.88%
71.35
57.32
24.48%
EBITDA
17.50
16.68
4.92%
19.66
15.23
29.09%
17.34
13.77
25.93%
20.63
11.48
79.70%
EBIDTM
20.73%
21.36%
21.84%
21.87%
21.66%
20.42%
22.43%
16.69%
Other Income
0.66
0.62
6.45%
0.22
0.23
-4.35%
0.28
0.40
-30.00%
0.58
1.46
-60.27%
Interest
2.20
2.73
-19.41%
2.71
2.41
12.45%
2.48
2.19
13.24%
3.06
1.67
83.23%
Depreciation
4.56
4.82
-5.39%
4.62
4.88
-5.33%
4.03
4.79
-15.87%
5.07
4.43
14.45%
PBT
11.39
9.75
16.82%
12.55
8.17
53.61%
11.12
7.20
54.44%
5.99
-9.68
-
Tax
2.87
2.07
38.65%
4.10
1.95
110.26%
2.77
1.79
54.75%
1.75
-2.28
-
PAT
8.52
7.68
10.94%
8.46
6.22
36.01%
8.35
5.40
54.63%
4.24
-7.40
-
PATM
10.10%
9.83%
9.39%
8.92%
10.42%
8.01%
4.61%
-10.76%
EPS
8.22
7.41
10.93%
8.16
6.01
35.77%
8.05
5.23
53.92%
4.21
-7.11
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
346.50
307.17
251.03
456.19
262.01
139.30
166.29
137.49
98.32
74.17
52.38
Net Sales Growth
22.01%
22.36%
-44.97%
74.11%
88.09%
-16.23%
20.95%
39.84%
32.56%
41.60%
 
Cost Of Goods Sold
167.73
89.63
69.44
141.83
165.59
87.08
119.44
101.59
71.29
56.77
38.67
Gross Profit
178.77
217.55
181.59
314.36
96.42
52.22
46.85
35.91
27.03
17.40
13.71
GP Margin
51.59%
70.82%
72.34%
68.91%
36.80%
37.49%
28.17%
26.12%
27.49%
23.46%
26.17%
Total Expenditure
271.37
240.86
190.30
284.52
233.15
125.08
150.58
125.81
89.41
69.15
49.11
Power & Fuel Cost
-
17.23
12.98
11.07
6.13
4.20
3.71
2.71
2.81
2.31
1.80
% Of Sales
-
5.61%
5.17%
2.43%
2.34%
3.02%
2.23%
1.97%
2.86%
3.11%
3.44%
Employee Cost
-
30.46
28.16
18.80
14.70
10.92
7.74
4.89
3.60
2.16
1.60
% Of Sales
-
9.92%
11.22%
4.12%
5.61%
7.84%
4.65%
3.56%
3.66%
2.91%
3.05%
Manufacturing Exp.
-
75.33
50.12
68.37
6.87
3.54
2.87
5.16
2.64
1.41
1.28
% Of Sales
-
24.52%
19.97%
14.99%
2.62%
2.54%
1.73%
3.75%
2.69%
1.90%
2.44%
General & Admin Exp.
-
17.66
16.11
9.10
12.80
8.46
5.83
3.18
2.58
2.77
1.36
% Of Sales
-
5.75%
6.42%
1.99%
4.89%
6.07%
3.51%
2.31%
2.62%
3.73%
2.60%
Selling & Distn. Exp.
-
8.71
12.66
35.13
26.09
10.60
10.79
8.06
5.04
3.29
4.06
% Of Sales
-
2.84%
5.04%
7.70%
9.96%
7.61%
6.49%
5.86%
5.13%
4.44%
7.75%
Miscellaneous Exp.
-
1.83
0.83
0.23
0.97
0.28
0.19
0.23
1.46
0.44
4.06
% Of Sales
-
0.60%
0.33%
0.05%
0.37%
0.20%
0.11%
0.17%
1.48%
0.59%
0.67%
EBITDA
75.13
66.31
60.73
171.67
28.86
14.22
15.71
11.68
8.91
5.02
3.27
EBITDA Margin
21.68%
21.59%
24.19%
37.63%
11.01%
10.21%
9.45%
8.50%
9.06%
6.77%
6.24%
Other Income
1.74
1.83
2.94
3.51
1.59
3.66
0.61
0.80
1.21
0.36
0.42
Interest
10.45
10.39
6.61
2.92
2.68
2.52
2.29
2.21
1.95
1.22
1.04
Depreciation
18.28
19.56
14.96
10.69
6.49
4.43
3.12
2.98
2.51
1.69
1.30
PBT
41.05
38.20
42.10
161.57
21.27
10.92
10.91
7.30
5.65
2.48
1.35
Tax
11.49
7.48
6.29
41.63
6.38
2.71
3.35
2.87
2.37
1.19
0.55
Tax Rate
27.99%
24.05%
24.60%
25.77%
30.00%
24.82%
30.71%
39.32%
41.95%
47.98%
40.74%
PAT
29.57
23.80
19.37
119.99
15.15
8.32
7.56
4.54
3.37
1.55
0.91
PAT before Minority Interest
29.74
23.62
19.28
119.94
14.89
8.21
7.56
4.42
3.28
1.28
0.80
Minority Interest
0.17
0.18
0.09
0.05
0.26
0.11
0.00
0.12
0.09
0.27
0.11
PAT Margin
8.53%
7.75%
7.72%
26.30%
5.78%
5.97%
4.55%
3.30%
3.43%
2.09%
1.74%
PAT Growth
148.49%
22.87%
-83.86%
692.01%
82.09%
10.05%
66.52%
34.72%
117.42%
70.33%
 
EPS
28.43
22.88
18.63
115.38
14.57
8.00
7.27
4.37
3.24
1.49
0.88

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
224.21
200.52
181.14
61.15
46.01
37.30
29.75
25.58
21.34
19.08
Share Capital
10.38
10.38
10.38
10.38
10.38
10.38
10.38
5.19
5.01
4.41
Total Reserves
213.84
190.14
170.77
50.78
35.63
26.92
19.37
20.40
16.75
14.81
Non-Current Liabilities
19.75
28.62
21.32
28.08
19.78
8.23
5.47
4.24
3.32
0.83
Secured Loans
19.56
27.19
19.59
16.26
8.18
7.01
3.11
2.63
2.35
0.30
Unsecured Loans
0.00
0.12
0.70
2.00
2.00
0.58
1.59
0.67
0.35
0.50
Long Term Provisions
0.22
0.90
0.75
0.68
0.62
0.52
0.55
0.54
0.17
0.00
Current Liabilities
151.85
125.95
139.49
78.29
67.75
60.83
61.98
41.60
26.54
17.41
Trade Payables
44.32
35.19
34.51
26.21
22.97
17.07
22.14
12.74
9.67
4.19
Other Current Liabilities
34.91
33.31
40.97
29.82
20.55
21.73
15.91
11.46
5.94
6.02
Short Term Borrowings
66.02
50.96
23.00
16.45
21.24
18.73
21.33
15.09
9.65
6.63
Short Term Provisions
6.60
6.48
41.00
5.80
3.00
3.30
2.60
2.30
1.28
0.58
Total Liabilities
394.18
353.64
340.60
166.22
132.50
105.38
96.21
70.92
51.20
37.32
Net Block
139.05
120.50
91.73
56.53
42.69
29.08
20.38
17.01
12.72
12.74
Gross Block
206.64
170.15
128.13
82.22
62.60
47.64
35.82
29.58
22.78
23.11
Accumulated Depreciation
69.21
49.65
36.39
25.69
19.91
18.56
15.44
12.56
10.06
10.37
Non Current Assets
151.49
146.43
112.77
60.33
43.46
29.99
21.14
17.75
12.88
12.86
Capital Work in Progress
0.00
14.29
12.15
2.89
0.00
0.00
0.00
0.00
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.73
0.65
0.79
0.63
0.62
0.03
0.03
Long Term Loans & Adv.
12.44
10.71
8.11
0.17
0.12
0.12
0.12
0.12
0.12
0.10
Other Non Current Assets
0.00
0.93
0.78
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
242.69
207.20
227.82
105.90
89.03
75.35
75.00
53.07
38.19
24.46
Current Investments
0.00
0.00
0.00
4.44
3.34
4.04
4.71
3.03
1.91
0.97
Inventories
78.39
86.31
53.36
17.36
22.42
11.25
15.03
13.85
10.35
6.46
Sundry Debtors
114.39
71.69
69.13
35.71
30.33
38.43
37.03
22.61
18.03
9.05
Cash & Bank
5.94
7.36
12.95
5.81
1.54
1.40
1.61
2.99
1.35
1.03
Other Current Assets
43.97
0.00
0.00
0.09
31.41
20.24
16.61
10.58
6.56
6.94
Short Term Loans & Adv.
36.94
41.83
92.38
42.49
31.29
20.18
16.49
10.53
6.50
6.91
Net Current Assets
90.84
81.25
88.33
27.61
21.28
14.52
13.02
11.47
11.65
7.05
Total Assets
394.18
353.63
340.59
166.23
132.49
105.37
96.21
70.92
51.21
37.32

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
42.98
41.38
60.60
26.71
6.16
13.58
-0.57
4.30
-2.85
PBT
31.10
25.57
161.57
21.27
10.92
10.91
7.30
5.65
2.48
Adjustment
36.62
20.95
13.56
9.09
7.09
5.22
4.36
4.69
3.25
Changes in Working Capital
-23.44
1.01
-73.18
2.72
-9.13
0.89
-9.17
-3.62
-7.31
Cash after chg. in Working capital
44.28
47.54
101.95
33.09
8.87
17.02
2.49
6.72
-1.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1.30
-6.16
-41.35
-6.38
-2.71
-3.44
-3.06
-2.42
-1.26
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-26.40
-48.44
-62.93
-23.20
-17.80
-11.78
-6.20
-7.26
-2.47
Net Fixed Assets
-22.20
-44.16
-55.17
-22.50
-14.92
-11.81
-6.25
-6.79
Net Investments
0.00
0.00
5.17
-1.18
0.92
0.08
-1.87
-1.99
Others
-4.20
-4.28
-12.93
0.48
-3.80
-0.05
1.92
1.52
Cash from Financing Activity
-17.40
0.99
5.66
0.77
11.77
-2.00
5.39
4.60
5.63
Net Cash Inflow / Outflow
-0.81
-6.07
3.33
4.27
0.14
-0.21
-1.38
1.65
0.31
Opening Cash & Equivalents
3.07
9.13
5.81
1.54
1.40
1.61
2.99
1.35
1.03
Closing Cash & Equivalent
2.26
3.07
9.13
5.81
1.54
1.40
1.61
2.99
1.35

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
215.31
192.48
173.81
58.16
43.57
35.14
27.83
23.79
20.78
20.89
ROA
6.32%
5.55%
47.33%
9.97%
6.90%
7.50%
5.29%
5.37%
2.90%
2.21%
ROE
11.16%
10.15%
99.66%
28.21%
20.10%
23.13%
16.51%
14.41%
6.54%
4.43%
ROCE
13.57%
12.27%
95.32%
26.36%
18.49%
21.91%
19.19%
19.74%
12.45%
9.61%
Fixed Asset Turnover
1.63
1.68
4.34
3.62
2.53
3.98
4.20
3.76
3.23
2.35
Receivable days
110.56
102.38
41.94
46.00
90.08
82.82
79.17
75.44
66.62
55.06
Inventory Days
97.85
101.54
28.29
27.71
44.10
28.84
38.34
44.92
41.35
48.10
Payable days
161.90
183.20
78.14
54.20
56.97
49.86
49.48
45.68
36.66
43.53
Cash Conversion Cycle
46.51
20.73
-7.91
19.51
77.22
61.80
68.03
74.67
71.31
59.64
Total Debt/Equity
0.44
0.45
0.35
0.68
0.77
0.79
0.92
0.77
0.62
0.43
Interest Cover
3.99
4.87
56.38
8.93
5.32
5.76
4.31
3.89
3.02
2.30

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Kwality Pharma - Quarterly Results
    31st Jan 2025, 18:54 PM

    Read More
  • Kwality Pharmaceuticals gets nod to start pre-clinical toxicity studies for Erythropoietin product
    2nd Jan 2025, 15:29 PM

    This milestone marks a significant step forward in its commitment to expanding its biologics portfolio and addressing critical healthcare needs

    Read More
  • Kwality Pharmaceuticals gets product approval for Tamoxifen tablet in South Africa
    24th Dec 2024, 15:59 PM

    This approval further strengthens its presence in the High Regulated and global oncology market

    Read More
  • Kwality Pharmaceutical gets approval for manufacturing and sale of PEGylated-Asparaginase
    26th Nov 2024, 15:59 PM

    L-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.